Novel insights in pharmacogenetics of drug response in Parkinson’s disease

Author： Arbouw Maurits EL Guchelaar Henk-Jan Egberts Toine CG

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.11, Iss.2, 2010-02, pp. : 127-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Non-dopaminergic drug treatment of Parkinson’s disease

By Müller T.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 557-572

Informa Healthcare

Access to resources Recommend Favorite

Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1083-1085

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment Benefit and Daily Drug Costs Associated with Treating Parkinsons Disease in a Parkinsons Disease Clinic

By Müller T.

CNS Drugs, Vol. 18, Iss. 2, 2004-01 ,pp. : 105-111

Adis International

Access to resources Recommend Favorite

Drug treatment of non-motor symptoms in Parkinson’s disease

By Müller Thomas

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 4, 2002-04 ,pp. : 381-388

Informa Healthcare

Access to resources Recommend Favorite

-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson’s Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 630-637

Bentham Science Publishers

Access to resources Recommend Favorite